A Single Institution's Experience of Definitive Radiotherapy Using Volumetric-modulated Arc Therapy for Hypopharyngeal Cancers

Anticancer Res. 2020 Jul;40(7):4183-4190. doi: 10.21873/anticanres.14418.

Abstract

Background/aim: The present study aimed to analyze the treatment outcome after definitive radiotherapy (dRT) using volumetric-modulated arc therapy (VMAT) in patients with hypopharyngeal cancer (HPC), including an examination of late toxicities.

Patients and methods: A total of 62 patients with HPC, who underwent dRT using VMAT, were analyzed. Overall survival (OS), progression-free survival (PFS), laryngoesophageal dysfunction-free survival (LEDFS), and locoregional control (LRC) were calculated.

Results: The median follow-up period was 49 months. The 3- and 5-year OS, PFS, LEDFS, and LRC rates were 77% and 60%, 61% and 56%, 66% and 53%, and both 79%, respectively. Regarding late toxicities, 11 (17.7%) patients developed grade ≥2 late toxicity. Grade 3 dysphagia was observed in 4 (6.5%) patients, and grade 2 xerostomia in 6 (9.7%).

Conclusion: VMAT was an effective treatment for HPC, with a low incidence of late toxicities.

Keywords: Hypopharyngeal cancer; laryngoesophageal dysfunction-free survival; volumetric-modulated arc therapy.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Agents / therapeutic use
  • Cisplatin / therapeutic use
  • Female
  • Humans
  • Hypopharyngeal Neoplasms / drug therapy
  • Hypopharyngeal Neoplasms / mortality
  • Hypopharyngeal Neoplasms / radiotherapy*
  • Kaplan-Meier Estimate
  • Male
  • Middle Aged
  • Progression-Free Survival
  • Radiotherapy, Intensity-Modulated* / adverse effects

Substances

  • Antineoplastic Agents
  • Cisplatin